Active Ingredient(s):Dacomitinib FDA Approved: * September 27, 2018 Pharm Company: *PFIZER INC Category:Cancer
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.
Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing[...
* May have multiple approval dates, manufacturers, or labelers.